Ocumension Therapeutics (1477) Fundamentals 2026 — Revenue Analysis | SniperIQ
Ocumension Therapeutics (1477) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$4.8B, trading at HK$5.95 on the HKSE. This SniperIQ fundamentals page covers Ocumension Therapeutics's valuation, profitability (net margin -19.7%), revenue (¥804M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ocumension Therapeutics's market cap?
Ocumension Therapeutics (1477) has a market capitalization of approximately HK$4.8B, trading at HK$5.95 on the HKSE. Market cap moves with the live share price.
What is Ocumension Therapeutics's P/E ratio?
Ocumension Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ocumension Therapeutics?
Ocumension Therapeutics runs a net profit margin of -19.7%, a gross margin of 44.9%, and an operating margin of -19.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ocumension Therapeutics generate?
Ocumension Therapeutics reported revenue of ¥804M for fiscal year 2025, with net income of -¥159M and earnings per share (EPS) of -0.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ocumension Therapeutics pay a dividend?
Ocumension Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Ocumension Therapeutics financially healthy?
Ocumension Therapeutics carries a debt-to-equity ratio of 0.05x and a current ratio of 3.70x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ocumension Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ocumension Therapeutics (1477) the key facts are: market cap HK$4.8B, revenue ¥804M, 52-week range 4.04-12.23. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ocumension Therapeutics's full fundamentals live
Get Ocumension Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.